# 64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)

> **NCT05407311** · PHASE2 · COMPLETED · sponsor: **Clarity Pharmaceuticals Ltd** · enrollment: 53 (actual)

## Conditions studied

- Biochemical Recurrence of Malignant Neoplasm of Prostate

## Interventions

- **DRUG:** 64Cu-SAR-BBN

## Key facts

- **NCT ID:** NCT05407311
- **Lead sponsor:** Clarity Pharmaceuticals Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-19
- **Primary completion:** 2024-05-13
- **Final completion:** 2024-05-13
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05407311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05407311, "64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05407311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*